Showing results (181-190 of 270) with videos related to

Sort By:
Pageof 27
ESMO Open|October 6, 2020
Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive casesElisabetta Di Liso, Michele Bottosso, Marcello Lo Mele, et al.
Clinical & Experimental Metastasis|May 29, 2025
Prospective multicentre study of patients with cutaneous metastases from breast cancer treated with electrochemotherapyFrancesco Russano, Giacomo Corrado, Antonio Bonadies, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2026
Analysis of SLFN11 expression in small cell lung cancer, carcinoids and large cell neuroendocrine carcinoma: insights into lung neuroendocrine neoplasmsDaniela Scattolin, Frank W J Heijboer, Giulia Pigato, et al.
The Oncologist|August 21, 2023
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World SettingLaura Bonanno, Martina Lorenzi, Davide Massa, et al.
Frontiers in Oncology|June 28, 2019
Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III DiseaseMaria Vittoria Dieci, Vassilena Tsvetkova, Gaia Griguolo, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 27, 2026
Multidisciplinary approach to bone metastases: a single center experience in a tertiary cancer centerChiara Pittarello, Antonella Brunello, Evelina Lamberti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancerValentina Guarneri, Daniele Giulio Generali, Antonio Frassoldati, et al.
European Journal of Cancer (Oxford, England : 1990)|January 20, 2024
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancerSara M Tolaney, Valentina Guarneri, Jae Hong Seo, et al.
Breast Cancer Research and Treatment|August 10, 2007
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancerValentina Guarneri, Antonio Frassoldati, Guido Ficarra, et al.
NPJ Breast Cancer|December 24, 2025
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implicationsGaia Griguolo, Michele Bottosso, Laia Paré, et al.
Pageof 27